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Early administration of adjuvant therapy for breast cancer is
intended to eliminate or suppress post-surgical residual disease to
the extent that the onset of local recurrence or distant metastasis is
delayed or prevented. Achievement of these goals depend, at least
in part, on treatment being initiated soon after surgery and before
the development of visible lesions. Needless and harmful treat-
ment, however, must be avoided. Traditionally, decisions as to
whether or not and how to treat breast cancer patients after surgery
have been heavily contingent on the accuracy of estimating the
behaviour and outcome of the disease, as well as of predicting
the response of the disease to a specific therapeutic regimen
(Gasparini et al, 1993).
Many clinical, histopathological and biochemical features of
breast cancer have been demonstrated to have prognostic utility,
although comparatively few of these markers have been shown to
have value for predicting the success of adjuvant treatment. None
of the numerous available prognostic markers, however, provides
precise information on the disease outcome, especially for an indi-
vidual patient. Furthermore, many of these markers do not provide
prognostic information independent of other factors, and many are
also difficult and costly to evaluate (McGuire and Clark, 1992;
Gasparini et al, 1993). Improved capability of predicting breast
cancer prognosis and response to treatment may likely be obtained
through the identification of newer markers. Considering the
complexity of cancer biology and the diversity of cancer cells, the
application of new and existing markers in combination may also
be an approach to facilitate accurate prediction.
Mutation of the p53 tumour suppressor gene occurs in approxi-
mately 20–50% of breast carcinomas (Soussi et al, 1994), and has
been reported to be associated with unfavourable prognosis in this
disease (Sjogren et al, 1996). In the majority of cases, the p53
mutation is predominantly mis-sense and leads to confirmational
alteration of the protein, its accumulation in tumour cell nuclei,
and consequently the utility of immunohistochemical staining
methods or ELISAs for the detection of p53 protein as simple
substitutes for mutational analyses (Thor et al, 1992; Allred et al,
1993; Borg et al, 1995, de Witte et al, 1996). Our recent study of a
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large cohort of breast cancer patients also suggested that p53
protein levels in breast cancer extracts measured by an enzyme-
linked immunosorbent assay (ELISA) were highly correlated with
the risks of both relapse and death, and that these relationships
were independent of other clinical and pathological features of the
disease (Levesque et al, 1998).
PSA, a tissue specific protein used as a tumour marker for the
diagnosis and management of prostate cancer (Partin and
Oesterling, 1994), has been found to be present in a number of
female tissues and body fluids (Pollen and Dreilinger, 1984;
Pummer et al, 1992; Clements and Mukhtar, 1994; Diamandis et
al, 1994, 1996; Yu and Diamandis, 1995a, 1995b; Yu et al, 1995a).
Studies have shown that both normal and abnormal (including
cancerous) breast tissues are capable of producing this protein (Yu
et al, 1994a, 1996), expression of which is up-regulated by andro-
gens and progestins through their receptors (Yu et al, 1994b;
Zarghami et al, 1997), and that the presence of PSA in breast
cancer may be indicative of a favourable prognosis (Yu et al,
1995b, 1998).
Because of the biological significance of p53 in cancer develop-
ment and progression, as well as the substantial clinical applica-
tions of PSA in prostate cancer management, these molecules are
two of the most extensively studied proteins in cancer research.
Although previous studies have suggested potential clinical uses
of each of these proteins for breast cancer prognosis, a study of
their combined value for indicating patient prognosis has not yet
been reported. In this study, the use of p53 and PSA in combina-
tion to predict the prognosis of breast cancer was prompted by
observations that these biochemical markers apparently indicate
different breast cancer prognoses, that they likely involve different
aspects of tumour cell biology, and that their expression levels in
breast tissue are not directly correlated. Using two highly sensitive
and specific immunoassays, PSA and p53 concentrations in
extracts of more than 900 breast cancer specimens were measured
and assessed with respect to their prognostic values, individually
and in combination using Cox regression survival analysis.
MATERIALS AND METHODS
Breast cancer specimens
The Ethics and Research Committee at the University of Toronto
and the Institutional Review Board at the University of Texas
Health Science Center at San Antonio each granted approval for
this study. The collection of tumour tissue specimens and patient
information has been described in detail elsewhere (Levesque et
al, 1998; Yu et al, 1998) and is summarized briefly here. Tumour
specimens from 1000 female breast cancer patients were obtained
from the Breast Cancer Tissue Resource at the University of Texas
Health Center at San Antonio, which maintains a large collection
of leftover tissue specimens sent from 165 health care institutions
throughout the USA to the Nichols Institute Research Laboratories
for routine quantification of oestrogen receptors (ER) and proges-
terone receptors (PR) and for flow cytometric analyses of tumour
cells. All patients included in the study had histologically
confirmed diagnoses of primary breast carcinoma, had been oper-
ated between August 1985 and October 1991, and had been char-
acterized for a number of clinical and pathological variables,
including age at surgery, number of lymph nodes positive for
malignancy, tumour size, ER and PR concentrations, DNA ploidy,
S phase fraction, receipt of endocrine therapy, radiotherapy and
chemotherapy, and survival times and outcomes. Of the patients
studied, 97% underwent modified radical mastectomy with axil-
lary lymph node dissection and 3% had incisional biopsy or
lumpectomy with axillary lymph node dissection. Forty-five per
cent of patients who had axillary lymph node dissection had posi-
tive nodes. The sizes of the tumours resected ranged from 0.1 to
14.5 cm and the median size was 2.3 cm. ER-positive or PR-posi-
tive lesions were found in 80% and 71% of the patients respec-
tively. Flow cytometric analyses showed 31% of patients to have
an S phase fraction above the cut-off level (³ 6.7%) and 54% of
patients to have an aneuploid DNA content. Patients who received
post-surgical treatment included those who were administered
regional radiotherapy alone (9%), adjuvant chemotherapy alone
(16%), endocrine therapy alone (17%), both endocrine and radia-
tion therapies (4%), both chemotherapy and radiotherapy (7%),
both systemic adjuvant therapies (6%) and all three therapy types
(2%). Patient follow-up times ranged from 7 to 121 months and
had a median value of 73 months. The disease-free survival (DFS)
time was defined as the time interval between the date of surgery
and the date of the first documented evidence of local or regional
axillary recurrence, distant metastasis, or new breast cancer. The
overall survival (OS) time was defined as the interval between the
date of surgery and the date of death due to any causes, or the date
of last follow-up for those patients still alive at the termination of
the study.
Quantification of p53, PSA and other markers
The methods used for the preparation of tumour tissue extracts as
well as for the measurements of p53 and PSA have been described
elsewhere (Levesque et al, 1998; Yu et al, 1998). In brief, concen-
trations of p53 and PSA were measured with two time-resolved
fluorometric immunoassays developed in our laboratory which
employ two pairs of well-characterized antibodies in a sandwich
configuration. The analytical performances of the assays,
including precision, specificity and sensitivity, have been evalu-
ated and documented previously (Levesque et al, 1995b; Ferguson
et al, 1996). All specimens were measured in duplicate and the
concentrations of each analyte were adjusted for the protein
contents of the extracts, determined by a commercial kit (Pierce
Chemical Co., Rockford, IL, USA). As described in detail else-
where, ER and PR concentrations were determined using dual
ligand binding assays (Dressler et al, 1988); cut-off levels for
receptor positivity were 3 fmol mg–1 and 5 fmol mg–1 for ER and
PR respectively (Clark and McGuire, 1983). The preparation of
specimens and performance of flow cytometric assessments of the
percentage of cells in S phase and the DNA content have also been
reported elsewhere (Dressler et al, 1988). The cut-off value for S
phase fraction considered a favourable prognostic indicator was
6.7% (Clark et al, 1989).
Statistical analysis
The relationships between the expression status of p53 and PSA
and patient survival were assessed using Cox proportional hazards
regression models of DFS and OS (Cox, 1972). PSA and p53 were
evaluated dichotomously in the models using cut-off points equal
to the 30th and 50th percentiles of the distributions of PSA and
p53 respectively. Selections of these cut-offs were based on the
individual prognostic values of each of these markers in our
previous studies (Levesque et al, 1998; Yu et al, 1998). PSA(+)patients and p53(–) patients served as the reference groups for the
calculation of the relative risks (RRs). Interactions between PSA
and p53 were also examined in the Cox regression models, which
contained the dichotomous PSA and p53 variables in addition to
their product term. This term was created by multiplying the PSA
and p53 variables, when each variable was coded as either –1 or
+1 on the basis of the cut-off points defined previously, resulting
in a two-category interaction term also having values of –1 or +1.
Correlation between concentrations of p53 and PSA were evalu-
ated by the calculation of the Spearman correlation coefficient.
In order to evaluate the combined prognostic value of PSA and
p53 in comparison to their individual values in prognosis, a three-
level ordinal variable was created using the combined categories
of PSA and p53. The first level of this new variable consisted of
patients whose tumour extracts were both PSA(+) and p53(–). The
second level included patients whose tumours were either positive
for both markers, i.e. PSA(+) and p53(+), or negative for both, i.e.
PSA(–) and p53(–). Patients in the third level had tumours which
were both PSA(–) and p53(+). The Cox regression models were
developed at both univariate and multivariate levels in order to
evaluate the independent impact of the combined PSA and p53
variable, on DFS and OS. Only patients for whom complete infor-
mation was collected were included in the multivariate analysis,
which incorporated the following covariables: age at surgery,
nodal status, tumour size, ER status, PR status, DNA ploidy, S
phase fraction and post-operative treatment, including endocrine
therapy, chemotherapy and radiation therapy. Kaplan–Meier
survival curves were also constructed to demonstrate the effects of
PSA and p53 in combination on DFS and OS probabilities (Kaplan
and Meier, 1958), differences over time for which were evaluated
using the log-rank test (Mantel, 1966).
RESULTS
The concentrations of PSA and p53 in the 952 breast tumour
extracts for which sufficient volume permitted assay of both
proteins varied widely, and the frequency distributions of the data
were extremely skewed towards the lower values for both of the
variables. The mean, standard deviation (s.d.) and median
of the PSA concentrations ranging from 0 to 19 629 ng g–1 were
150.1 ng g–1, 1078 ng g–1, and 6.0 ng g–1 respectively. The concen-
trations of p53 ranged from 0 to 58.02 mg g–1 and were distributed
with a mean of 1.28 mg g–1, a s.d. of 4.52 mg g–1 and a median of
0.17 mg g–1. Correlation between p53 and PSA concentrations was
not evident (r = –0.016, P = 0.271).
As demonstrated in our previous study (Yu et al, 1998), PSA
used as a categorical variable was associated inversely with
tumour size (P = 0.032), S phase fraction (P = 0.002) and DNA
aneuploidy (P = 0.004) in contingency tables analysed by c2 tests;
no association was found between PSA and patient age (P =
0.517), nodal status (P = 0.393) and steroid receptor status (P =
0.72 for ER and P = 0.28 for PR) in the same analyses. With
respect to p53 protein status (Levesque et al, 1998) considered in
relation to the same variables, a positive association was found
with S phase fraction (P = 0.04) and DNA aneuploidy (P = 0.005),
whereas ER and PR were inversely associated with p53-positive
tumours (P = 0.003 for ER and P = 0.05 for PR). Patient age (P =
0.13), tumour size (P = 0.19) and nodal status (P = 0.63) were not
associated with p53 protein status.
The Cox regression models were developed initially with two
separate variables, PSA and p53, and both were statistically signif-
icant in the models; for PSA-negativity, the RRs were 1.20 (P =
0.01) for relapse and 1.18 (P = 0.06) for death, whereas for p53-
positivity, the RRs were 1.19 (P = 0.02) for relapse and 1.18 (P =
0.03) for death. These results, shown in Table 1, demonstrate 20%
and 18% increases in risks for relapse and death, respectively,
associated with tumour extract PSA levels below the cut-off point
for positivity. p53-positivity was similarly associated with a 19%
increased risk for relapse and an 18% increased risk for death,
relative to p53-negative tumours. Introduction of the interaction
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Table 1 Univariate associations of expression status of prostate specific
antigen (PSA) and p53 with disease-free and overall survivala
Variable statusb Number RR 95% CI P-value
Unadjusted disease-free survival (n = 952)
PSA(+) 626 1.00
PSA(–) 326 1.20 1.04–1.41 0.014
p53(–) 476 1.00
p53(+) 476 1.19 1.03–1.37 0.017
PSA(+)p53(–) 364 1.00
PSA(±)p53(±)c 460 1.43 1.18–1.75
PSA(–)p53(+) 128 2.04 1.39–3.13 <0.001
Unadjusted overall survival (n = 952)
PSA(+) 626 1.00
PSA(–) 326 1.18 0.99–1.39 0.059
p53(–) 476 1.00
p53(+) 476 1.18 1.02–1.36 0.028
PSA(+)p53(–) 364 1.00
PSA(±)p53(±)c 460 1.39 1.11–1.72
PSA(–)p53(+) 128 1.92 1.25–2.94 0.003
aRR = relative risk estimated using the Cox proportional hazard regression
model; CI = confidence interval; P-values are two-sided. bCut-off points for
PSA- and p53-positivity were 1 ng g–1 and 0.16 mg g–1 respectively. cIndicates
either PSA(+)p53(+) or PSA(–)p53(–).
Table 2 Multivariate associations of expression status of prostate specific
antigen (PSA) and p53 with disease-free and overall survivala
Variable statusb Number RR 95% CI P-value
Adjusted disease-free survival (n = 838)c
PSA(+) 633 1.00
PSA(–) 205 1.47 1.06–2.00 0.020
p53(–) 408 1.00
p53(+) 430 1.46 1.08–1.97 0.017
PSA(+)p53(–) 319 1.00
PSA(±)p53(±)d 403 1.45 1.18–1.82
PSA(–)p53(+) 116 2.13 1.39–3.23 <0.001
Adjusted overall survival (n = 838)c
PSA(+) 633 1.00
PSA(–) 205 1.49 1.05–2.13 0.023
p53(–) 408 1.00
p53(+) 430 1.41 1.03–1.93 0.033
PSA(+)p53(–) 319 1.00
PSA(±)p53(±)d 403 1.45 1.15–1.82
PSA(–)p53(+) 116 2.08 1.33–3.33 0.001
aRR = relative risk estimated using the Cox proportional hazard regression
model; CI = confidence interval; P-values are two-sided. bCut-off points for
PSA- and p53-positivity were 1 ng g–1 and 0.16 mg g–1 respectively.
cMultivariate analysis adjusted for age, nodal status, tumour size, DNA ploidy,
S phase fraction, oestrogen receptor status, progesterone receptor status,
and receipt of endocrine therapy, chemotherapy and radiotherapy. dIndicates
either PSA(+)p53(+) or PSA(–)p53(–).p53 and PSA for breast cancer prognosis 493
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term, which was not statistically significant when evaluated alone
in the models (P = 0.66 for DFS and P = 0.46 for OS), into the Cox
analysis resulted in very little reduction in the random variation
attributed to the models. Substantial changes in the risks of relapse
and death were indicated when the two markers were combined
together in the analysis (Table 1). The maximum risk differences
were approximately 100% when the comparison was made
between the two extreme groups, i.e. comparing patients with the
anticipated best prognosis [PSA(+) and p53(–)] with those having
the worst expected outcome [PSA(–) and p53(+)]. The RR for
relapse was 2.04 (P < 0.001), and the RR for death was 1.92 (P =
0.003). Patients in the other group who were either negative or
positive for both markers had intermediate risks for relapse (RR =
1.43) and death (RR = 1.39).
Figures 1 and 2 show the Kaplan–Meier DFS and OS curves
among the four groups of patients having different combinations of
positivity status for PSA and p53, demonstrating similar differences
in survival as observed in the Cox regression analysis. Evident from
the Figures are that patients whose tumour extracts were positive for
PSA and simultaneously negative for p53 had survival probabilities
which were consistently the highest over time, and that patients
whose tumours were PSA-negative and p53-positive had consis-
tently the lowest survival rates. The difference in survival proba-
bility between the two extreme groups was more evident in terms of
DFS than OS. The survival probabilities for patients in the two
groups with negative or positive status for both markers did not
differ significantly.
Shown in Table 2 are the results of the Cox regression analysis
of DFS and OS in which risks for each outcome were adjusted for
several clinical and pathological variables. The RRs for relapse
and death of the combined PSA and p53 variable were not altered
markedly after their adjustment in the multivariate analysis, in that
the twofold statistically significant differences in risks of relapse
and death between the two extreme groups were maintained.
However, the RRs for the individual PSA and p53 variables were
increased in magnitude after the adjustment. The risks of relapse
and death for PSA-negative patients were almost 50% higher
compared to PSA-positive patients. The p53-positive patients had
more than 40% increased risks of relapse and death in comparison
to p53-negative patients. Both estimates of RR were statistically
significant.
In the multivariate analysis, variables which were also statisti-
cally significant in the Cox regression model were nodal status
(RR = 1.52, 95% confidence intervals (CI) = 1.25–1.84, P < 0.001
for DFS, and RR = 1.69, 95% CI 1.40–2.04, P < 0.001 for OS) and
tumour size (RR = 1.38, 95% CI 1.00–1.89, P = 0.047 for DFS,
and RR = 1.43, 95% CI 1.02–1.98, P = 0.036 for OS). Patients
who received chemotherapy also showed a significantly increased
risk of relapse in the multivariate model (RR = 1.76, 95% CI
1.28–2.42,  P < 0.001), a finding which was not seen in OS analysis
and was likely due to the selection of patients exhibiting local
recurrence or metastasis for receipt of chemotherapy. None of the
steroid hormone receptors, or DNA ploidy or the S phase fraction
were shown to be independent prognostic factors in the multi-
variate analysis (data not shown).
DISCUSSION
No study has yet evaluated PSA and p53 in combination for breast
cancer prognosis. The concept of using these proteins together
to predict the survival outcome of breast cancer was based on
findings that PSA and p53 expression indicated favourable and
unfavourable prognoses, respectively, and that improved predic-
tion may be offered by considering them together. Further support
for this notion is provided by the absence of known functional
associations between the proteins, and the lack of statistical inter-
action between them in relation to patient survival.
Much greater differences in risks of relapse and death were
observed when PSA and p53 were utilized in combination
compared to use of the two markers individually. Furthermore,
adjustment of the associations with other variables showed little
impact on the risks for relapse and death conferred by using the
combined variable of PSA and p53. However, PSA and p53 used
separately in the survival analysis were shown substantial changes
when the relationships were adjusted for other clinical and patho-
logical factors. This observation suggests that use of these markers
in combination in survival analysis generates more consistent and
reliable results for prognosis than use of the markers individually.
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Figure 1 Kaplan–Meier disease-free (A) and overall (B) survival analysis of
breast cancer patients divided into four groups based on the expression
status of both p53 and prostate specific antigen (PSA) proteins. p53 status
and PSA status were based upon cut-off points equal to the median
(0.16 mg g–1), and the 30th percentile (1 ng g–1), of the frequency distributions
of p53 and PSA concentrations respectively494 H Yu et al
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There is presently no experimental evidence implying a direct
biological link between PSA and p53. Comparison of the levels of
the two proteins in breast cancer tissues in our preliminary study
did not find any indication that their tissue concentrations were
correlated to each other (Levesque et al, 1995a) – a finding
confirmed in the present study. However, a possible indirect rela-
tionship between PSA and p53 has been suggested with respect to
one of the insulin-like growth factor binding proteins, IGFBP-3. It
has been shown that wild-type p53 can transcriptionally up-regu-
late expression of IGFBP-3 (Buckbinder et al, 1995), which can
serve as a substrate for proteolysis in seminal plasma by PSA
(Cohen et al, 1992).
PSA is a glycoprotein which, until recently, has been believed to
be produced and secreted exclusively by the epithelial cells of the
prostate, and therefore has been used widely as a tumour marker in
the diagnosis and management of prostate cancer (Partin and
Oesterling, 1994). The expression of PSA has been found to be
present in a number of female organs (Pollen and Dreilinger, 1984;
Pummer et al, 1992; Clements and Mukhtar, 1994; Diamandis et
al, 1994, 1996; Yu and Diamandis, 1995a, 1995b; Yu et al, 1995a)
including breast tissue (Yu et al, 1994a, 1996), in which its produc-
tion has been shown to be up-regulated by androgens and prog-
estins via their specific receptors (Yu et al, 1994b; Zarghami et al,
1997). Moreover, in a cell culture system, oestrogens were demon-
strated to impair the PSA production induced by androgens (Yu et
al, 1994b). In a small-scale clinical study, PSA status in extracts of
breast tumours was shown to be associated with the risk of breast
cancer relapse (Yu et al, 1995b). This finding has been confirmed
and extended in a large cohort study (Yu et al, 1998), in which we
observed that the risks of both relapse and death were significantly
reduced in patients with PSA-positive breast cancer compared to
those with PSA-negative lesions, and these associations were
independent of other prognostic indicators, such as nodal status,
tumour size and steroid hormone receptor status.
Both the physiological function of PSA in breast tissue, and the
cellular basis for the favourable prognosis associated with its
expression, remain unknown. Based on in vitro observations of
breast cancer cell lines that the PSA gene is regulated by several
steroid hormones through their receptors (Yu et al, 1994b; Zarghami
et al, 1997), we have speculated that the presence of PSA could indi-
cate either the preservation of a steroid regulatory pathway in well-
differentiated cancer cells, or the suppression of an oestrogenic
impact on these cells by androgen (Yu et al, 1995b). However, our
observations also invoke a possible role for PSA in growth factor
regulation (Oesterling et al, 1989; Cohen et al, 1992, 1994).
The important biological functions of p53 in cell cycle regulation
and programmed cell death have been well established (Hartwell
and Kastan, 1994; Lane, 1994; Levine et al, 1994). Loss of these
cellular functions consequent to p53 gene mutation has been consid-
ered to be highly relevant to cancer development and progression
(Chang et al, 1993; Greenblatt et al, 1994; Karp and Broder, 1995)
and occurs in 20–50% of breast cancers (Soussi et al, 1994). Breast
cancer patients with p53 mutation have been shown to be more
likely to develop relapse or to die compared to those without p53
mutation (Sjogren et al, 1996). Although findings from many studies
have suggested potential clinical implications of the detection of p53
gene mutations, the implementation of mutational analysis for p53
remains rather complex and costly. Because mis-sense p53 gene
mutation, accounting for over 80% of all p53 genetic abnormalities,
typically results in p53 protein accumulation in tumour cell nuclei,
the detection of p53 protein by immunochemical methods has been
shown to be highly correlated with mutation of the p53 gene. This
method has therefore been considered a simple and rapid alternative
to the assessment of p53 gene mutational status by molecular
biology techniques (Thor et al, 1992; Allred at al, 1993; de Witte et
al, 1996). The validity of immunohistochemical detection of p53
protein is further supported by findings of studies using ELISA to
measure the protein (Borg et al, 1995; de Witte et al, 1996). A recent
study by our group also demonstrated that the risks of relapse or
death were elevated significantly with increased concentrations
of p53 protein in extracts of breast carcinomas and that this
dose–response relationship was independent of other prognostic
indicators (Levesque et al, 1998). Although requiring less skilled
labour and interpretation than the detection of p53 gene alterations
by mutational analysis, immunostaining for p53 protein remains
arguably more subjective and qualitative than ELISA, which may
yield more reproducible and inherently quantitative results
(Diamandis and Levesque, 1995). Furthermore, a direct comparison
of ELISA-determined p53 concentrations in tumour extracts with
the mutational status of the p53 gene, determined by DNA
sequencing of p53 exons 5–9 in a series of ovarian carcinomas, has
been recently performed by our group and has revealed the general
concordance between mis-sense point mutation in the core domain
and overexpression of p53 protein (Lianidou et al, 1999).
From a clinical perspective, ELISA-type immunoassays for the
evaluation of p53 and PSA may offer a number of strengths over
immunohistochemistry. In practice, ELISAs may more easily
process a large number of specimens with short assay time and at a
low cost. Furthermore, results from ELISAs are more reproducible
and objective. Although ELISAs require the preparation of soluble
extracts of tissue specimens of greater mass than needed for
sectioning and immunostaining, and provides no information on
the expression of the protein in the context of intracellular or histo-
logical features, these limitations are offset by the quantitative
nature of the results and the potentially smaller bias in tissue
sampling. Moreover, the adoption of ELISA methods for p53
detection by clinical laboratories would be facilitated further by
the present availability of cytosolic extracts of breast tumours
prepared for routine ER and PR determinations.
In summary, by evaluating the prognostic value of ELISA-quan-
tified PSA and p53 in combination in more than 900 patients with
breast cancer, we conclude that the determination of concentra-
tions of both proteins in breast tumour extracts provides superior
prognostic information than assessment of the individual markers.
Studies in other patient populations, however, especially those
with well-defined post-operative treatment, are needed to confirm
our finding.
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